Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420267 | 0.91 | APP (0.54) | APPENPP2PARP10 | |
| SCHEMBL27550091 | 0.84 | MAOB (0.80) | MAOBAPPNR4A2PARP10 | |
| SCHEMBL15331901 | 0.84 | ENPP2 (0.45) | MAOBAPPENPP2NR4A2 | |
| SCHEMBL17006749 | 0.84 | LPL (0.47) | MAOBENPP2 | |
| SCHEMBL16687441 | 0.84 | APP (0.47) | APPENPP2PARP10 | |
| SCHEMBL31558408 | 0.83 | CYP1A2 (0.49) | ENPP2 | |
| SCHEMBL2557358 | 0.82 | ENPP2 (0.68) | MAOBAPPENPP2 | |
| SCHEMBL16687435 | 0.82 | MAOB (0.58) | MAOBAPPENPP2PARP10 | |
| SCHEMBL2559504 | 0.82 | MAOB (0.61) | MAOBAPPENPP2NR4A2 | |
| SCHEMBL1982099 | 0.82 | ENPP2 (0.68) | MAOBAPPENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-3107908-B1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-02-12 | — | — | US | disclosed |
| EP-3110801-B1 | 6-ARYL-4-PHENYLAMINO-QUINAZOLINE ANALOGS AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | COUNCIL SCIENT IND RES (IN) | 2019-01-30 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-10106504-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2358704-A1 | 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase | Pfizer Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | PFIZER INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010049841-A1 | 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | PFIZER INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885APP 1838/4885ENPP2 147/4885 |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | MAOB 1887/4885APP 3808/4885ENPP2 2566/4885 |
| US-10202374-B2 | 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors | PIK3CA, PI4KA, PDPK1 | MAOB 1514/4885APP 4126/4885ENPP2 1308/4885 |
| US-10106504-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DUT | MAOB 823/4885APP 2438/4885ENPP2 2123/4885 |
| US-20100113465-A1 | 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS | FAAH, FAAH2, APEH | MAOB 248/4885APP 565/4885ENPP2 19/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | MAOB 3377/4885APP 735/4885ENPP2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.